SLC25A5P1: A Potential Drug Target and Biomarker for Mitochondrial Carrier gene

Target Name: SLC25A5P1

NCBI ID: G266623

SLC25A5P1

Other Name(s): Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 pseudogene 1 | ANTP3 | bK250D10.4 | BK250D10.4 | solute carrier family 25 member 5 pseudogene 1

SLC25A5P1: A Potential Drug Target and Biomarker for Mitochondrial Carrier gene

Introduction

Mitochondria are organelles responsible for generating the majority of the energy for the cell during the respiratory chain process. They are also involved in the synthesis of adenosine, a crucial molecule for maintaining cellular homeostasis. The protein SLC25A5P1, belonging to the Absolutely Controlled Carrier (ACC ) family 25, is a mitochondrial carrier that functions as an adenine nucleotide translocator. In this article, we will discuss the potential implications of SLC25A5P1 as a drug target and biomarker.

Potential Drug Target

SLC25A5P1 is a protein that can be targeted by small molecules due to its unique structure. It consists of a long N-terminus, a transmembrane region, and a C-terminus. The N-terminus of SLC25A5P1 contains a putative ATP-binding site, which suggests that it could be a potential drug target.

SLC25A5P1 functions as an adenine nucleotide translocator, which means it translocates the amino acid adenine into the mitochondrial matrix. Adenine is a crucial molecule for maintaining cellular homeostasis, and its levels have been linked to a number of diseases, including heart disease, neurodegenerative disorders, and cancer. Therefore, targeting SLC25A5P1 could potentially lead to new therapeutic approaches for these diseases.

Biomarker

SLC25A5P1 can also serve as a biomarker for some diseases. For example, increased SLC25A5P1 levels have been observed in individuals with certain forms of cancer, which could indicate an increased risk of disease. Additionally, SLC25A5P1 levels have been correlated with the expression of certain genes involved in cell death and stress, which could make it an attractive target for drugs that aim to improve cellular homeostasis.

Expression and Regulation

SLC25A5P1 is expressed in most tissues and cells, but its levels are highly regulated. It is expressed in the mitochondria, where it is primarily localized to the matrix, and in the cytoplasm. The level of SLC25A5P1 expression varies depending on the cell type and the environment.

SLC25A5P1 is regulated by several factors, including its own gene products, as well as those of its downstream targets. For example, SLC25A5P1 has been shown to be regulated by the transcription factor, p53. p53 is a well-known regulator of gene expression that has been implicated in numerous diseases, including cancer.

Functions and Interactions

SLC25A5P1 functions as an adenine nucleotide translocator by participating in the transfer of adenine from the cytoplasm to the mitochondrial matrix. This process is critical for maintaining cellular homeostasis and is also involved in the production of reactive oxygen species (ROS), which can contribute to oxidative stress and inflammation.

SLC25A5P1 is also involved in the regulation of mitochondrial dynamics, which is critical for maintaining cellular homeostasis. It interacts with several other proteins, including the transcription factor, p53, to regulate mitochondrial translation and fusion.

Conclusion

SLC25A5P1 is a protein that has significant implications for our understanding of cellular homeostasis and the regulation of mitochondrial dynamics. Its unique structure and function as an adenine nucleotide translocator make it an attractive target for small molecules. Additionally, its regulation by the transcription factor, p53 , suggests that it may play a role in various diseases, including cancer

Protein Name: Solute Carrier Family 25 Member 5 Pseudogene 1

The "SLC25A5P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A5P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets